GSK plc
GSK
$37.56
$0.411.10%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.27% | 54.21% | 21.95% | -104.07% | -27.21% |
| Total Depreciation and Amortization | 92.06% | 48.89% | -50.66% | 68.81% | 42.48% |
| Total Amortization of Deferred Charges | -- | -- | 7.16% | -- | -- |
| Total Other Non-Cash Items | 75.56% | 424.46% | 305.44% | -365.39% | -369.06% |
| Change in Net Operating Assets | -37.79% | -129.08% | -128.73% | 562.89% | 52.83% |
| Cash from Operations | 99.42% | 18.71% | -24.87% | 0.08% | -14.18% |
| Capital Expenditure | 10.24% | 16.70% | -15.40% | -4.84% | -2.82% |
| Sale of Property, Plant, and Equipment | 164.73% | -0.67% | 798.43% | -90.66% | -32.81% |
| Cash Acquisitions | 90.37% | -10.47% | -3,250.75% | 93.47% | 97.63% |
| Divestitures | -323.57% | 66.89% | 26.36% | -54.16% | -111.02% |
| Other Investing Activities | -132.72% | -116.05% | -177.19% | -212.81% | 67.72% |
| Cash from Investing | -185.95% | -662.59% | -530.47% | -53.02% | 180.50% |
| Total Debt Issued | -- | -- | 195.17% | -- | -- |
| Total Debt Repaid | -163.76% | 43.16% | 18.23% | -25.05% | 15.58% |
| Issuance of Common Stock | 100.00% | -33.33% | -100.00% | -- | -66.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -6.54% | -7.02% | -11.08% | -10.94% | -17.97% |
| Other Financing Activities | 31.75% | -20.00% | -102.91% | 74.23% | 16.58% |
| Cash from Financing | -58.57% | 180.40% | 75.83% | 27.67% | -5,249.55% |
| Foreign Exchange rate Adjustments | -244.15% | 42.50% | 121.23% | -251.93% | 85.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -437.33% | 411.95% | 338.65% | 950.78% | -7.49% |